Pure Bioscience Stock Beta
| PUREDelisted Stock | USD 0.09 0.03 26.83% |
Pure Bioscience fundamentals help investors to digest information that contributes to Pure Bioscience's financial success or failures. It also enables traders to predict the movement of Pure Pink Sheet. The fundamental analysis module provides a way to measure Pure Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pure Bioscience pink sheet.
Pure |
Pure Bioscience Company Beta Analysis
Pure Bioscience's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Pure Bioscience Beta | 0.25 |
Most of Pure Bioscience's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pure Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Pure Bioscience has a Beta of 0.2476. This is 79.87% lower than that of the Household Products sector and 79.87% lower than that of the Consumer Staples industry. The beta for all United States stocks is notably lower than that of the firm.
Pure Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pure Bioscience's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pure Bioscience could also be used in its relative valuation, which is a method of valuing Pure Bioscience by comparing valuation metrics of similar companies.Pure Bioscience is currently under evaluation in beta category among its peers.
As returns on the market increase, Pure Bioscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pure Bioscience is expected to be smaller as well.
Pure Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (2.02) % | ||||
| Operating Margin | (1.98) % | ||||
| Current Valuation | 13.51 M | ||||
| Shares Outstanding | 111.36 M | ||||
| Shares Owned By Insiders | 41.23 % | ||||
| Number Of Shares Shorted | 222.97 K | ||||
| Price To Earning | 12.49 X | ||||
| Price To Book | 3.85 X | ||||
| Price To Sales | 8.00 X | ||||
| Revenue | 1.85 M | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (3.27 M) | ||||
| Net Income | (3.49 M) | ||||
| Cash And Equivalents | 511 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 239 K | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 2.02 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (2.42 M) | ||||
| Short Ratio | 2.56 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.25 | ||||
| Market Capitalization | 13.36 M | ||||
| Total Asset | 4.48 M | ||||
| Retained Earnings | (103.22 M) | ||||
| Working Capital | 3.61 M | ||||
| Current Asset | 6.14 M | ||||
| Current Liabilities | 2.54 M | ||||
| Z Score | 0.8 | ||||
| Net Asset | 4.48 M |
About Pure Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pure Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pure Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pure Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |